Life
Trump Administration Advances Drug Pricing Legislation with Pharma Stakeholders
The White House has initiated discussions on drug pricing reforms by sharing drafted legislative text with major pharmaceutical companies, while also addressing Chinese biotech licensing.
Editorial Staff
1 min read
On March 30, 2026, the Trump administration circulated legislative text concerning drug pricing reforms to over a dozen leading pharmaceutical companies.
This move signals a strategic push to engage industry stakeholders in shaping the policy framework aimed at reducing drug costs.
In parallel, the administration is also exploring issues related to Chinese biotech licensing, indicating a broader focus on international biotech dynamics.